Skip to main content
Erschienen in: Drugs 8/2020

01.06.2020 | Review Article

Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease

verfasst von: Nirosen Vijiaratnam, Thomas Foltynie

Erschienen in: Drugs | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease is a chronic, neurodegenerative disease, which manifests with a mixture of motor, cognitive and behavioural symptoms. Levodopa is the most effective antiparkinsonian treatment to date, although chronic use engenders a mixture of complications in a substantial proportion of patients. Amongst these is the occurrence of episodes of worsening symptoms—‘off’ phenomena. These episodes can manifest with either motor or non-motor symptoms or a combination of these features and have been found to have profound impacts on patients’ quality of life. Although preventative measures are poorly evidenced, avoiding excessive total daily levodopa intake in selected populations that are deemed to be of a higher risk for developing these episodes warrants further exploration. Methods to improve levodopa bioavailability and delivery to the brain are currently available and are of value in addressing these episodes once they have become established. These include modifications to levodopa formulations as well as the use of complimentary agents that improve levodopa bioavailability. The deployment of device-assisted approaches is a further dimension that can be considered in addressing these debilitating episodes. This review summarises the clinical manifestations of ‘off’ phenomena and the current approaches to treat them. Although we briefly discuss clinical advances on the horizon, the predominant focus is on existing, established treatments.
Literatur
1.
Zurück zum Zitat Mayeux R, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1996;143(5):528 (Am. J. Epidemiol: 1995). Mayeux R, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1996;143(5):528 (Am. J. Epidemiol: 1995).
2.
Zurück zum Zitat Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of parkinson’s disease. Arch Neurol. 1993;50(2):140–8.PubMed Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of parkinson’s disease. Arch Neurol. 1993;50(2):140–8.PubMed
8.
Zurück zum Zitat Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55(11 Suppl 4):S13–20.PubMed Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55(11 Suppl 4):S13–20.PubMed
26.
Zurück zum Zitat Van Lunen B, Anthony J, Spears J. Implications of motor fluctuations in Parkinson’s disease patients on chronic therapy (IMPACT): results from an observational registry. Mov Disord. 2005;20:S146. Van Lunen B, Anthony J, Spears J. Implications of motor fluctuations in Parkinson’s disease patients on chronic therapy (IMPACT): results from an observational registry. Mov Disord. 2005;20:S146.
34.
Zurück zum Zitat Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.PubMed Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.PubMed
55.
Zurück zum Zitat Frackowiak RS, Leenders KL, Poewe WH, Palmer AJ, Brenton DP. Inhibition of L-18Ffluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986;20(2):258–62.PubMed Frackowiak RS, Leenders KL, Poewe WH, Palmer AJ, Brenton DP. Inhibition of L-18Ffluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986;20(2):258–62.PubMed
65.
Zurück zum Zitat Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology. 1989;39(11 Suppl 2):7–10.PubMed Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology. 1989;39(11 Suppl 2):7–10.PubMed
66.
Zurück zum Zitat De La Fuente-Fernndez R, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001. https://doi.org/10.1002/ana.65. De La Fuente-Fernndez R, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001. https://​doi.​org/​10.​1002/​ana.​65.
74.
Zurück zum Zitat Hsu A, Yao HM, Gupta S, Modi NB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa–levodopa–entacapone (Stalevo®). J Clin Pharmacol. 2015. https://doi.org/10.1002/jcph.514.PubMedPubMedCentral Hsu A, Yao HM, Gupta S, Modi NB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa–levodopa–entacapone (Stalevo®). J Clin Pharmacol. 2015. https://​doi.​org/​10.​1002/​jcph.​514.PubMedPubMedCentral
76.
Zurück zum Zitat Destée A, Rérat K, Bourdeix I. Is there a difference between levodopa/dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson’s disease patients experiencing symptom re-emergence due to wearing-off? The honeymoon study. Eur Neurol. 2009. https://doi.org/10.1159/000177938.PubMed Destée A, Rérat K, Bourdeix I. Is there a difference between levodopa/dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson’s disease patients experiencing symptom re-emergence due to wearing-off? The honeymoon study. Eur Neurol. 2009. https://​doi.​org/​10.​1159/​000177938.PubMed
80.
Zurück zum Zitat Cotzias GC, Papavasiliou PS, Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology. 1968;18(3):276–7.PubMed Cotzias GC, Papavasiliou PS, Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology. 1968;18(3):276–7.PubMed
83.
Zurück zum Zitat Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37(1):23–7.PubMed Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37(1):23–7.PubMed
92.
Zurück zum Zitat Navon N, Gendreau R, Meckler J. Gastric retention of the accordion Pill™: results from MRI studies with Parkinson’s disease patients and healthy volunteers [abstract]. Mov Disord. 2018;33(suppl 2). Navon N, Gendreau R, Meckler J. Gastric retention of the accordion Pill™: results from MRI studies with Parkinson’s disease patients and healthy volunteers [abstract]. Mov Disord. 2018;33(suppl 2).
94.
Zurück zum Zitat LeWitt P, Gendreau R, Meckler J, Navon N. Design of a phase 3 efficacy and safety trial of accordion Pill™ carbidopa/levodopa for Parkinson’s disease (PD) patients experiencing motor fluctuations [abstract]. Mov Disord. 2018;33(suppl 2). LeWitt P, Gendreau R, Meckler J, Navon N. Design of a phase 3 efficacy and safety trial of accordion Pill™ carbidopa/levodopa for Parkinson’s disease (PD) patients experiencing motor fluctuations [abstract]. Mov Disord. 2018;33(suppl 2).
109.
112.
Zurück zum Zitat Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48(4):1070–7.PubMed Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48(4):1070–7.PubMed
121.
Zurück zum Zitat Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998;21(3):141–51.PubMed Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998;21(3):141–51.PubMed
142.
Zurück zum Zitat Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–3.PubMedPubMedCentral Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–3.PubMedPubMedCentral
157.
Zurück zum Zitat Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002. https://doi.org/10.1124/jpet.102.039867.PubMed Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002. https://​doi.​org/​10.​1124/​jpet.​102.​039867.PubMed
175.
Zurück zum Zitat Grosset KA, Malek N, Morgan F, Grosset DG. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol. 2013. https://doi.org/10.1111/ene.12091.PubMed Grosset KA, Malek N, Morgan F, Grosset DG. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol. 2013. https://​doi.​org/​10.​1111/​ene.​12091.PubMed
177.
180.
Zurück zum Zitat Taddei RN, Spinnato F, Jenner P. New symptomatic treatments for the management of motor and nonmotor symptoms of Parkinson’s disease. Int Rev Neurobiol. 2017;132:407–52. Taddei RN, Spinnato F, Jenner P. New symptomatic treatments for the management of motor and nonmotor symptoms of Parkinson’s disease. Int Rev Neurobiol. 2017;132:407–52.
211.
Zurück zum Zitat Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson’s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract. 2017. https://doi.org/10.1002/mdc3.12416.PubMed Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson’s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract. 2017. https://​doi.​org/​10.​1002/​mdc3.​12416.PubMed
217.
Zurück zum Zitat Giladi N, Caraco Y, Gurevich T, Djaldetti R, Adar L, Rachmilewitz Minei T, Oren S. ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD [abstract]. Mov Disord. 2017;32(suppl:2). Giladi N, Caraco Y, Gurevich T, Djaldetti R, Adar L, Rachmilewitz Minei T, Oren S. ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD [abstract]. Mov Disord. 2017;32(suppl:2).
218.
Zurück zum Zitat Giladi N, et al. Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations: results of a phase IIa dose finding study. Eur J Neurol. 2015. https://doi.org/10.1111/ene.12805. Giladi N, et al. Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson’s disease (PD) patients with motor fluctuations: results of a phase IIa dose finding study. Eur J Neurol. 2015. https://​doi.​org/​10.​1111/​ene.​12805.
219.
Zurück zum Zitat Adar L, Minei TR, Cohen Y. Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel). Mov Disord. 2017. https://doi.org/10.1002/mds.27087. Adar L, Minei TR, Cohen Y. Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel). Mov Disord. 2017. https://​doi.​org/​10.​1002/​mds.​27087.
220.
Zurück zum Zitat Adar L, Rachmilewitz Minei T, Cohen Y, Oren S. Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel) [abstract]. Mov Disord. 2017;32(suppl:2). Adar L, Rachmilewitz Minei T, Cohen Y, Oren S. Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel) [abstract]. Mov Disord. 2017;32(suppl:2).
221.
Zurück zum Zitat Oren S, Kieburtz K, Olanow CW, Cohen Y. A randomized controlled clinical study to evaluate the efficacy and safety of subcutaneous levodopa/carbidopa (ND0612H) in patients with advanced Parkinson’s disease. J Parkinsons Dis. 2016. https://doi.org/10.3233/JPD-169900. Oren S, Kieburtz K, Olanow CW, Cohen Y. A randomized controlled clinical study to evaluate the efficacy and safety of subcutaneous levodopa/carbidopa (ND0612H) in patients with advanced Parkinson’s disease. J Parkinsons Dis. 2016. https://​doi.​org/​10.​3233/​JPD-169900.
253.
Zurück zum Zitat Wolz M, Hauschild J, Koy J, Fauser M, Klingelhöfer L, Schackert G, Reichmann H, Storch A. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(8):994–7.PubMed Wolz M, Hauschild J, Koy J, Fauser M, Klingelhöfer L, Schackert G, Reichmann H, Storch A. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(8):994–7.PubMed
Metadaten
Titel
Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease
verfasst von
Nirosen Vijiaratnam
Thomas Foltynie
Publikationsdatum
01.06.2020
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 8/2020
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01310-2

Weitere Artikel der Ausgabe 8/2020

Drugs 8/2020 Zur Ausgabe

AdisInsight Report

Ozanimod: First Approval